PSNL Shareholder Notice: Personalis $16.25 per Share Merger Under Investigation on Behalf of Shareholders
Law firm BFA investigating $16.25/share take-private of Personalis by Tempus AI, which owns 12.5% of PSNL.
What this release says
A law firm, Bleichmar Fonti & Auld, says it is investigating the proposed going-private merger of Personalis with Tempus AI, under which Personalis would be taken private at $16.25 per share. The firm is examining whether the deal terms comply with Delaware law and whether Tempus's prior business relationship with Personalis led to breaches of fiduciary duty. For a shareholder, the release is an invitation to contact the firm about possible legal options, not a statement that wrongdoing has occurred.
Key figures
- Proposed price per share
- $16.25
- Tempus AI stake in Personalis
- 12.5%
- Merger announced
- July 20, 2026
Positive for shareholders
- The proposed merger would pay shareholders $16.25 per share in a mix of cash and stock.
Negative for shareholders
- The firm is investigating whether the price is fair to public shareholders and whether the deal complies with Delaware law.
- Tempus AI already owns 12.5% of Personalis and has had a commercial relationship with it since November 2023, which the firm says may have caused breaches of fiduciary duty.
Written by Quantisnow AI from this release. Not financial advice.
Key terms
- Going private merger:
- A deal in which a buyer acquires all of a public company's shares so the company is no longer listed on a stock exchange.
- Breach of fiduciary duty:
- A failure by company directors or controlling parties to act in the best interests of shareholders.
- Contingency fee basis:
- A fee arrangement where the law firm is paid only if a recovery is obtained, usually as a share of that recovery.
FAQ
What is the Personalis merger being investigated?
Personalis is being taken private by Tempus AI at $16.25 per share in a merger that mixes cash and stock consideration, as announced on July 20, 2026.
Why is the firm investigating the Personalis deal?
The firm says it is examining whether the merger terms comply with Delaware law, whether Tempus's prior relationship with Personalis caused related breaches of fiduciary duty, and whether the price is fair to public shareholders.
Does the firm charge shareholders to participate?
The release says representation is on a contingency fee basis, so there is no cost to shareholders, and shareholders are not responsible for court costs or litigation expenses.
Historical context for PSNL
Across the 30 sessions after earlier PSNL headlines, the stock closed higher 13 times and lower 16 times, with a median move of 2.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | PSNL | SPY |
|---|---|---|---|
| Oct 21, 2026 | Personalis NeXT Personal® Data Showcasing Ultrasensitive MRD to be Presented at ESMO 2026 | -0.3% | +0.5% |
| Oct 20, 2026 | Personalis Brings Resistance Mutation Tracking to NeXT Personal® MRD Test | +0.4% | +0.3% |
| Oct 6, 2026 | Personalis downgraded by BTIG Research | -2.3% | +0.5% |
| Aug 24, 2026 | Personalis downgraded by Craig Hallum with a new price target | -7.2% | -0.3% |
| Aug 5, 2026 | Personalis Reports Second Quarter Results and Recent Highlights | +0.0% | -0.2% |
| Jul 14, 2026 | Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain | -0.1% | +0.4% |
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Medical Specialities
- Listed since
- 2019
Follow PSNL and get a push notification the moment its next story breaks.